Expert Interview
Revisiting the HELIOS-B data for vutrisiran in ATTR-CM following publication in NEJM and presentation at ESC
Ticker(s): ALNYInstitution: Providence St. Joseph Heart Institute
- Medical director of the Center for Cardiovascular Analytics, Research, and Data Science (CARDS) at the Providence St. Joseph Heart Institute in Portland, Oregon and an adjunct faculty member of the Ciccarone Center for the Prevention of Heart Disease at the Johns Hopkins Hospital in Baltimore, Maryland.
- Manages 675 patients with ASCVD & 11 patients with pericarditis.
- Principal clinical interests include identifying, coordinating, and implementing cardiovascular care improvement strategies.
Roughly how many patients do you treat with ATTR-CM?
Added By: wilson_adminWhat are your thoughts on the recent data from the HELIOS-B Phase 3 study of vutrisiran?
Added By: wilson_adminIf you had to rate your level of excitement on a 1 to 10 scale for the potential of vutrisiran, what would it be and why?
Added By: wilson_admin- What is the current landscape for diagnosing ATTR cardiomyopathy, and how has the diagnostic process evolved with the use of technologies like technetium pyrophosphate scanning?
- How does the efficacy of Tafamidis compare with Acoramidis and Vutrisiran, particularly considering the stabilizing effects and mortality benefits observed in clinical trials?
- Given the rising costs of therapies like Tafamidis, Acoramidis, and Vutrisiran, what are the potential financial challenges and considerations for patients, especially those covered under Medicare Part D?
- How does the HELIOS-B trial data inform treatment decisions regarding combination therapy with stabilizers and silencers for patients with worsening symptoms or cardiovascular events?
- For future therapies targeting transthyretin amyloid cardiomyopathy, such as next-generation agents, how might dosing frequency and silencing potency impact cardiovascular outcomes and treatment preferences?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
